Storyline
Advances in engineered immune cell therapies: in vivo CAR T cells, HIV-targeting CAR-T, and optimized NK cell transduction
Recent studies demonstrate significant progress in engineered immune cell therapies.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- bioRxiv preprints on immune cell engineeringbiorxiv.org